U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies

Molly A. Smith, Gaurav S. Choudhary, Andrea Pellagatti, Kwangmin Choi, Lyndsey C. Bolanos, Tushar D. Bhagat, Shanisha Gordon-Mitchell, Dagny Von Ahrens, Kith Pradhan, Violetta Steeples, Sanghyun Kim, Ulrich Steidl, Matthew Walter, Iain D.C. Fraser, Aishwarya Kulkarni, Nathan Salomonis, Kakajan Komurov, Jacqueline Boultwood, Amit Verma, Daniel T. Starczynowski

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Spliceosome mutations are common in myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML), but the oncogenic changes due to these mutations have not been identified. Here a global analysis of exon usage in AML samples revealed distinct molecular subsets containing alternative spliced isoforms of inflammatory and immune genes. Interleukin-1 receptor-associated kinase 4 (IRAK4) was the dominant alternatively spliced isoform in MDS and AML and is characterized by a longer isoform that retains exon 4, which encodes IRAK4-long (IRAK4-L), a protein that assembles with the myddosome, results in maximal activation of nuclear factor kappa-light-chain-enhancer of B cells (NF-κB) and is essential for leukaemic cell function. Expression of IRAK4-L is mediated by mutant U2 small nuclear RNA auxiliary factor 1 (U2AF1) and is associated with oncogenic signalling in MDS and AML. Inhibition of IRAK4-L abrogates leukaemic growth, particularly in AML cells with higher expression of the IRAK4-L isoform. Collectively, mutations in U2AF1 induce expression of therapeutically targetable ‘active’ IRAK4 isoforms and provide a genetic link to activation of chronic innate immune signalling in MDS and AML.

Original languageEnglish (US)
Pages (from-to)640-650
Number of pages11
JournalNature Cell Biology
Volume21
Issue number5
DOIs
StatePublished - May 1 2019

Fingerprint

Interleukin-1 Receptor-Associated Kinases
Acute Myeloid Leukemia
Protein Isoforms
Myelodysplastic Syndromes
Mutation
Neoplasms
Exons
Spliceosomes
Myeloid Cells
B-Lymphocytes
Light

ASJC Scopus subject areas

  • Cell Biology

Cite this

Smith, M. A., Choudhary, G. S., Pellagatti, A., Choi, K., Bolanos, L. C., Bhagat, T. D., ... Starczynowski, D. T. (2019). U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies. Nature Cell Biology, 21(5), 640-650. https://doi.org/10.1038/s41556-019-0314-5

U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies. / Smith, Molly A.; Choudhary, Gaurav S.; Pellagatti, Andrea; Choi, Kwangmin; Bolanos, Lyndsey C.; Bhagat, Tushar D.; Gordon-Mitchell, Shanisha; Von Ahrens, Dagny; Pradhan, Kith; Steeples, Violetta; Kim, Sanghyun; Steidl, Ulrich; Walter, Matthew; Fraser, Iain D.C.; Kulkarni, Aishwarya; Salomonis, Nathan; Komurov, Kakajan; Boultwood, Jacqueline; Verma, Amit; Starczynowski, Daniel T.

In: Nature Cell Biology, Vol. 21, No. 5, 01.05.2019, p. 640-650.

Research output: Contribution to journalArticle

Smith, MA, Choudhary, GS, Pellagatti, A, Choi, K, Bolanos, LC, Bhagat, TD, Gordon-Mitchell, S, Von Ahrens, D, Pradhan, K, Steeples, V, Kim, S, Steidl, U, Walter, M, Fraser, IDC, Kulkarni, A, Salomonis, N, Komurov, K, Boultwood, J, Verma, A & Starczynowski, DT 2019, 'U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies', Nature Cell Biology, vol. 21, no. 5, pp. 640-650. https://doi.org/10.1038/s41556-019-0314-5
Smith, Molly A. ; Choudhary, Gaurav S. ; Pellagatti, Andrea ; Choi, Kwangmin ; Bolanos, Lyndsey C. ; Bhagat, Tushar D. ; Gordon-Mitchell, Shanisha ; Von Ahrens, Dagny ; Pradhan, Kith ; Steeples, Violetta ; Kim, Sanghyun ; Steidl, Ulrich ; Walter, Matthew ; Fraser, Iain D.C. ; Kulkarni, Aishwarya ; Salomonis, Nathan ; Komurov, Kakajan ; Boultwood, Jacqueline ; Verma, Amit ; Starczynowski, Daniel T. / U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies. In: Nature Cell Biology. 2019 ; Vol. 21, No. 5. pp. 640-650.
@article{0570530abab442da94b370dc5b81f188,
title = "U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies",
abstract = "Spliceosome mutations are common in myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML), but the oncogenic changes due to these mutations have not been identified. Here a global analysis of exon usage in AML samples revealed distinct molecular subsets containing alternative spliced isoforms of inflammatory and immune genes. Interleukin-1 receptor-associated kinase 4 (IRAK4) was the dominant alternatively spliced isoform in MDS and AML and is characterized by a longer isoform that retains exon 4, which encodes IRAK4-long (IRAK4-L), a protein that assembles with the myddosome, results in maximal activation of nuclear factor kappa-light-chain-enhancer of B cells (NF-κB) and is essential for leukaemic cell function. Expression of IRAK4-L is mediated by mutant U2 small nuclear RNA auxiliary factor 1 (U2AF1) and is associated with oncogenic signalling in MDS and AML. Inhibition of IRAK4-L abrogates leukaemic growth, particularly in AML cells with higher expression of the IRAK4-L isoform. Collectively, mutations in U2AF1 induce expression of therapeutically targetable ‘active’ IRAK4 isoforms and provide a genetic link to activation of chronic innate immune signalling in MDS and AML.",
author = "Smith, {Molly A.} and Choudhary, {Gaurav S.} and Andrea Pellagatti and Kwangmin Choi and Bolanos, {Lyndsey C.} and Bhagat, {Tushar D.} and Shanisha Gordon-Mitchell and {Von Ahrens}, Dagny and Kith Pradhan and Violetta Steeples and Sanghyun Kim and Ulrich Steidl and Matthew Walter and Fraser, {Iain D.C.} and Aishwarya Kulkarni and Nathan Salomonis and Kakajan Komurov and Jacqueline Boultwood and Amit Verma and Starczynowski, {Daniel T.}",
year = "2019",
month = "5",
day = "1",
doi = "10.1038/s41556-019-0314-5",
language = "English (US)",
volume = "21",
pages = "640--650",
journal = "Nature Cell Biology",
issn = "1465-7392",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies

AU - Smith, Molly A.

AU - Choudhary, Gaurav S.

AU - Pellagatti, Andrea

AU - Choi, Kwangmin

AU - Bolanos, Lyndsey C.

AU - Bhagat, Tushar D.

AU - Gordon-Mitchell, Shanisha

AU - Von Ahrens, Dagny

AU - Pradhan, Kith

AU - Steeples, Violetta

AU - Kim, Sanghyun

AU - Steidl, Ulrich

AU - Walter, Matthew

AU - Fraser, Iain D.C.

AU - Kulkarni, Aishwarya

AU - Salomonis, Nathan

AU - Komurov, Kakajan

AU - Boultwood, Jacqueline

AU - Verma, Amit

AU - Starczynowski, Daniel T.

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Spliceosome mutations are common in myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML), but the oncogenic changes due to these mutations have not been identified. Here a global analysis of exon usage in AML samples revealed distinct molecular subsets containing alternative spliced isoforms of inflammatory and immune genes. Interleukin-1 receptor-associated kinase 4 (IRAK4) was the dominant alternatively spliced isoform in MDS and AML and is characterized by a longer isoform that retains exon 4, which encodes IRAK4-long (IRAK4-L), a protein that assembles with the myddosome, results in maximal activation of nuclear factor kappa-light-chain-enhancer of B cells (NF-κB) and is essential for leukaemic cell function. Expression of IRAK4-L is mediated by mutant U2 small nuclear RNA auxiliary factor 1 (U2AF1) and is associated with oncogenic signalling in MDS and AML. Inhibition of IRAK4-L abrogates leukaemic growth, particularly in AML cells with higher expression of the IRAK4-L isoform. Collectively, mutations in U2AF1 induce expression of therapeutically targetable ‘active’ IRAK4 isoforms and provide a genetic link to activation of chronic innate immune signalling in MDS and AML.

AB - Spliceosome mutations are common in myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML), but the oncogenic changes due to these mutations have not been identified. Here a global analysis of exon usage in AML samples revealed distinct molecular subsets containing alternative spliced isoforms of inflammatory and immune genes. Interleukin-1 receptor-associated kinase 4 (IRAK4) was the dominant alternatively spliced isoform in MDS and AML and is characterized by a longer isoform that retains exon 4, which encodes IRAK4-long (IRAK4-L), a protein that assembles with the myddosome, results in maximal activation of nuclear factor kappa-light-chain-enhancer of B cells (NF-κB) and is essential for leukaemic cell function. Expression of IRAK4-L is mediated by mutant U2 small nuclear RNA auxiliary factor 1 (U2AF1) and is associated with oncogenic signalling in MDS and AML. Inhibition of IRAK4-L abrogates leukaemic growth, particularly in AML cells with higher expression of the IRAK4-L isoform. Collectively, mutations in U2AF1 induce expression of therapeutically targetable ‘active’ IRAK4 isoforms and provide a genetic link to activation of chronic innate immune signalling in MDS and AML.

UR - http://www.scopus.com/inward/record.url?scp=85064756006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064756006&partnerID=8YFLogxK

U2 - 10.1038/s41556-019-0314-5

DO - 10.1038/s41556-019-0314-5

M3 - Article

C2 - 31011167

AN - SCOPUS:85064756006

VL - 21

SP - 640

EP - 650

JO - Nature Cell Biology

JF - Nature Cell Biology

SN - 1465-7392

IS - 5

ER -